After Hours Summary: USNA +15.4%, MODN +13.2%, LYFT +10.5% higher on earnings; AYX -8.8%, AKAM -7%, CSCO -5.4% lower on earningsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: USNA +15.4% (also authorizes $150 mln share repurchase program), MODN +13.2%, LYFT +10.5%, CCK +7.8%, OI +6.4%, ENPH +5.9%, URBN +5.9%, RICK +5.8%, STEP +4.6%, THC +3.8%, QGEN +3.6%, MESA +3.5%, GPRE +3.2%, TWTR +2.6%, MAT +2.3%, TWO +2.3%, BW +2.3% (also announces stock offering), RPD +2%, YELP +2%, BKH +0.1%, PRI +0.1% (also raises dividend; approves new buyback),
Companies trading higher in after hours in reaction to news: GNFT +103.8% (positive results from the Ph 2 clinical trial evaluating elafibranor), GMDA +71.6% (presents Phase 3 data on omidubicel; anticipates BLA submission in 2H21), KALV +3.3% (stock offering), MTCH +2.4% (to acquire Hyperconnect for US$1.725 bln in cash and stock), FULT +1.7% (approves $75 mln stock repurchase program), IVZ +1.4% (reports Jan AUM data), KTOS +1.1% (stock offering), WYNN +0.9% (WynnBET receives conditional approval for online sports betting in Tennessee), MRNA +0.7% (announces vaccine supply agreements with Taiwan and Colombia), SRG +0.2% (new CEO), IBM +0.2% (Instacart acquires over 250 patents from IBM), APAM +0.1% (reports Jan AUM data), SQZ +0.1% (stock offering),
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CPSI -13.4%, AYX -8.8%, ATEN -8.7%, AKAM -7% (also announces organizational changes), PAA -7%, CDAY -6.9%, CSCO -5.4% (also raises dividend), NCR -4%, NGL -3.6%, FMC -3%, DCPH -2.7%, VOYA -2.6%, MTW -2.5%, FISV -1.7%, EXTR -1.4%, WELL -0.9%, REYN -0.8% (also raises dividend), G -0.3% (also announces $500 mln increase to share repurchase auth; and 10% dividend increase), DEI -0.2%, HIW -0.2%,
Companies trading lower in after hours in reaction to news: VNRX -12% (stock offering), XONE -9.2% (stock offering), ENLV -8.7% (announces $10 mln bought deal offering), LMB -7.9% (stock offering), BLDP -6.4% (announces $350 mln bought deal offering), CDAK -4% (stock offering), MREO -2.3% (ADS offering), ONCR -2.2% (stock offering), SNY -0.6% (FDA approves Libtayo as immunotherapy for patients with advanced basal cell carcinoma), VRNS -0.3% (files for mixed securities shelf offering),